Clinical trials: sponsored by AstraZeneca
Gastroesophageal Reflux
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
This PMS study had the objective to evaluate under ordinary medical care conditions the efficacy and tolerability of esomeprazole in patients who where treated by general practitioners and internists.
- Trial name
- NCT00567021
- Volunteers
- 67,130 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
To characterize the burden of disease in GERD patients of prescription therapy'
- Trial name
- NCT00392002
- Testing
- Esomeprazole
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Prostate Cancer
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
The primary objective of this trial is to examine the value of prophylactic versus therapeutic breast radiotherapy in Casodex monotherapy induced gynaecomastia and/or breast pain.
- Trial name
- COMART (NCT00590213)
- Testing
- Casodex 150mg, Radiotherapy, Haematology
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Inoperable or Recurrent Rectal Cancer
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
The pilot study is designed to investigate the value of Neo-adjuvant Tomudez in combination with radiotherapy in patients with inoperable or recurrent rectal cancer in terms of response rate and increasing the resectability of…
- Trial name
- TOMUDEX (NCT00590278)
- Testing
- Tomudex, Radiotherapy, Haematology
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Asthma
Pulmicort Asthma Prevention (Post-PAC)
This prospective study will evaluate the feasibility of the defined decision tree for the treatment of asthmatic young children.
- Trial name
- NCT00233584
- Testing
- Pulmicort (budesonide) pMDI
- Where
- Denmark
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Asthma
SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults
The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma
- Trial name
- NCT00238784
- Testing
- Budesonide/formoterol Turbuhaler
- Where
- 3 sites in Canada
- Volunteers
- 1,300 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Proteinuria
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.
- Trial name
- NCT00242346
- Testing
- candesartan cilexetil
- Where
- 26 sites in Canada
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Pediatric Hypertension
Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age
Study 261A is a dose-ranging and safety study of candesartan cilexetil. It is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with a 4 week treatment period in hypertensive…
- Trial name
- NCT00244634
- Testing
- candsartan cilexetil
- Where
- 44 sites in United States, Belgium and 2 more
- Volunteers
- 238 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
- Trial name
- NCT00252798
- Testing
- Gefitinib, Carboplatin, Paclitaxel
- Where
- 2 sites in Australia
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tolerance of these treatments.
- Trial name
- NCT00333294
- Testing
- Gefitinib, Radiation therapy, Cisplatin
- Where
- 4 sites in France
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Colorectal Cancer
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in…
- Trial name
- NCT00234429
- Testing
- Gefitinib, raltitrexed
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Head and Neck Neoplasms
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
To determine the safety and tolerability of gefitinib in combination with cisplatin and radiation (3D-CRT or IMRT) in patients with locally advanced head and neck cancer.
- Trial name
- NCT00239304
- Testing
- Gefitinib, Cisplatin, Radiotherapy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Obsessive Compulsive Disorder
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
- Trial name
- NCT00254735
- Testing
- quetiapine fumarate, SSRI/Clomipramine
- Where
- 2 sites in Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling
The purpose of the study is to evaluate the efficacy of quetiapine compared to valproate during a 12 month treatment period in subjects with Bipolar Disorder I or II with Rapid Cycling.
- Trial name
- NCT00254774
- Testing
- quetiapine fumarate or valproate
- Where
- 3 sites in Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
The purpose of this study is to determine if combination therapy of weekly Taxotere™ with Iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer
- Trial name
- NCT00319618
- Testing
- Gefitinib, Docetaxel
- Where
- Norway
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is…
- Trial name
- NCT00296387
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 102 sites in Belgium, Canada and 9 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.
- Trial name
- NCT00335699
- Testing
- Rosuvastatin
- Where
- 7 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
In an observational multi-centre study (CHALLENGE), the effects were assessed of starting treatment with low doses of rosuvastatin in statin naive patients with a history of coronary heart disease (CHD), peripheral vascular…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, CVA
- Trial name
- CHALLENGE (NCT00574782)
- Volunteers
- 2,660 people
- Sponsor
- AstraZeneca